Sodium Iodide Symporter (NIS) in the Management of Patients with Thyroid Carcinoma
10.1007/s13139-018-0540-y
- Author:
June Key CHUNG
1
;
Hyun Woo KIM
;
Haewon YOUN
;
Gi Jeong CHEON
Author Information
1. Department of Nuclear Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. hkim0127@gmail.com
- Publication Type:Editorial
- Keywords:
Sodiumiodide symporter;
NIS;
Thyroid cancer;
Gene therapy;
Theranostics
- MeSH:
Genetic Therapy;
Humans;
Iodine;
Ion Transport;
Membrane Glycoproteins;
Sodium Iodide;
Sodium;
Theranostic Nanomedicine;
Thyroid Diseases;
Thyroid Gland;
Thyroid Neoplasms
- From:Nuclear Medicine and Molecular Imaging
2018;52(5):325-326
- CountryRepublic of Korea
- Language:English
-
Abstract:
Although radioiodine has been applied in thyroid diseases including carcinoma for over 70 years, it was only in 1996 that the basic molecular mechanism of iodine uptake was identified. Iodide is actively transported into the thyroid via a membrane glycoprotein known as sodium iodide symporter (NIS). NIS mediates radioiodine uptake into thyroid normal and cancer cells. The knowledge on NIS expression has provided scientific background to the empirical management of thyroid carcinoma. Based on recent studies of the NIS gene, this paper provides current clinical applications and future studies.
